{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T23:14:49Z","timestamp":1761779689327,"version":"build-2065373602"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.idc.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:31:19Z","timestamp":1755739879000},"page":"629-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the Medical Treatment of Clostridioides difficile Infection"],"prefix":"10.1016","volume":"39","author":[{"given":"Nirja","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2025.07.005_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fcimb.2018.00029","article-title":"Clostridioides difficile biology: sporulation, germination, and corresponding therapies for C. difficile infection","volume":"8","author":"Zhu","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"issue":"18","key":"10.1016\/j.idc.2025.07.005_bib2","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. Hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.idc.2025.07.005_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. Burden of","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2025.07.005_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12879-016-1610-3","article-title":"Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach","volume":"16","author":"Desai","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"24","key":"10.1016\/j.idc.2025.07.005_bib5","first-page":"2369","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cmi.2021.09.026","article-title":"Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review","volume":"28","author":"van Rossen","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib7","doi-asserted-by":"crossref","first-page":"ofae127","DOI":"10.1093\/ofid\/ofae127","article-title":"Characteristics of patients with initial","volume":"11","author":"Guh","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2025.07.005_bib8","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s40121-023-00856-4","article-title":"Screening for asymptomatic Clostridioides difficile carriage among hospitalized patients: a narrative review","volume":"12","author":"Gilboa","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/CMR.00016-13","article-title":"Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories","volume":"26","author":"Burnham","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1086\/511798","article-title":"Recommendations for surveillance of Clostridium difficile-associated disease","volume":"28","author":"McDonald","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00676-22","article-title":"Validation of clinical risk models for Clostridioides difficile-attributable outcomes","volume":"66","author":"Madden","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cmi.2017.11.017","article-title":"Microbiologic factors affecting Clostridium difficile recurrence","volume":"24","author":"Chilton","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.idc.2025.07.005_bib16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/cid\/cix529","article-title":"Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection","volume":"65","author":"Sirbu","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/cid\/ciab233","article-title":"A tapered-pulsed fidaxomicin regimen following treatment in patients with multiple Clostridioides difficile infection recurrences","volume":"73","author":"Skinner","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib18","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2025.07.005_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2025.07.005_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/23744235.2020.1800080","article-title":"Review of high dose vancomycin in the treatment of Clostridioides difficile infection","volume":"52","author":"Bader","year":"2020","journal-title":"Infect Dis (Lond)"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMclde2204692","article-title":"Oral vancomycin as secondary prophylaxis for prevention of recurrent Clostridioides difficile infection","volume":"388","author":"Chang","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.idc.2025.07.005_bib25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1017\/ice.2020.277","article-title":"Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: a systematic review and meta-analysis","volume":"41","author":"Babar","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/antibiotics11020183","article-title":"Oral vancomycin prophylaxis for primary and secondary prevention of Clostridioides difficile infection in patients treated with systemic antibiotic therapy: a systematic review, meta-analysis and trial sequential analysis","volume":"11","author":"Maraolo","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idc.2025.07.005_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1756284821994046","article-title":"Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis","volume":"14","author":"Tariq","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib28","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-031807","article-title":"Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection","volume":"148","author":"Bao","year":"2021","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17834","article-title":"Oral vancomycin prophylaxis for prevention of recurrent Clostridioides difficile infection: double-blinded placebo-controlled randomized clinical trial","volume":"8","author":"Keating","year":"2025","journal-title":"JAMA Open Network"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2025.07.005_bib30","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55 Suppl 2","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2025.07.005_bib31","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile","volume":"55 Suppl 2","author":"Babakhani","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jiac.2020.02.014","article-title":"Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile","volume":"26","author":"Hamada","year":"2020","journal-title":"J Infect Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhin.2015.01.015","article-title":"Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin","volume":"90","author":"Biswas","year":"2015","journal-title":"J Hosp Infect"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/cit346","article-title":"Is fidaxomicin worth the cost? An economic analysis","volume":"57","author":"Bartsch","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jval.2012.11.004","article-title":"Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States","volume":"16","author":"Stranges","year":"2013","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.idc.2025.07.005_bib37","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dku257","article-title":"Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection","volume":"69","author":"Nathwani","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.36469\/9903","article-title":"Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infection (C. Difficile-associated diarrhoea) in Ireland","volume":"2","author":"van Engen","year":"2015","journal-title":"J Health Econ Outcomes Res"},{"issue":"11","key":"10.1016\/j.idc.2025.07.005_bib39","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s10096-015-2472-0","article-title":"Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain","volume":"34","author":"Rubio-Terres","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2025.07.005_bib40","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1128\/AAC.00939-15","article-title":"Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection","volume":"59","author":"Gallagher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s15010-016-0894-y","article-title":"A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany","volume":"44","author":"Watt","year":"2016","journal-title":"Infection"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/phar.2049","article-title":"Fidaxomicin versus vancomycin as a first-line treatment for Clostridium difficile-associated diarrhea in specific patient populations: a pharmacoeconomic evaluation","volume":"37","author":"Reveles","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/13696998.2017.1302946","article-title":"Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France","volume":"20","author":"Watt","year":"2017","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.idc.2025.07.005_bib44","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/jac\/dky184","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged >\/=60 years (EXTEND): analysis of cost-effectiveness","volume":"73","author":"Cornely","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciz318","article-title":"Cost-effectiveness of treatment regimens for Clostridioides difficile infection: an evaluation of the 2018 infectious diseases society of America guidelines","volume":"70","author":"Rajasingham","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40121-021-00480-0","article-title":"Budget impact analysis of fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection in the United States","volume":"11","author":"Jiang","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib47","article-title":"Fidaxomicin as a salvage therapy for fulminant Clostridioides difficile infection","volume":"13","author":"Heleno","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.idc.2025.07.005_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijscr.2017.11.042","article-title":"A case report of successful management of clostridium difficile colitis with antegrade Fidaxomicin through a mucous fistula obviating the need for subtotal colectomy","volume":"42","author":"Arnott","year":"2018","journal-title":"Int J Surg Case Rep"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib49","article-title":"Local application of fidaxomicin in a patient with subtotal colectomy following recurring Clostridium difficile infection","volume":"1","author":"Pavel","year":"2014","journal-title":"JMM Case Rep"},{"key":"10.1016\/j.idc.2025.07.005_bib50","first-page":"91","article-title":"Fidaxomicin use in the pediatric population with Clostridioides difficile","volume":"14","author":"Oliver","year":"2022","journal-title":"Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.idc.2025.07.005_bib51","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/cid\/ciz1149","article-title":"Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE)","volume":"71","author":"Wolf","year":"2020","journal-title":"Clin Infect Dis"},{"year":"2018","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria","key":"10.1016\/j.idc.2025.07.005_bib53"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciac817","article-title":"Reference susceptibility testing and genomic surveillance of Clostridioides difficile, United States, 2012-17","volume":"76","author":"Gargis","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jac\/dkae101","article-title":"Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences","volume":"79","author":"Kolte","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2025.07.005_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab365","article-title":"Reduced susceptibility to metronidazole is associated with initial clinical failure in Clostridioides difficile infection","volume":"8","author":"Gonzales-Luna","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciae087","article-title":"Reduced vancomycin susceptibility in Clostridioides difficile is associated with lower rates of initial cure and sustained clinical response","volume":"79","author":"Eubank","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib58","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/cid\/ciaf028","article-title":"Emergence and spread of Clostridioides difficile isolates with reduced fidaxomicin susceptibility in an acute care hospital","volume":"80","author":"Redmond","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262597","article-title":"Prevalence and antimicrobial resistance pattern of Clostridium difficile among hospitalized diarrheal patients: a systematic review and meta-analysis","volume":"17","author":"Dilnessa","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkz513","article-title":"Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates","volume":"75","author":"Shen","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib62","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/jac\/dkab231","article-title":"Mechanisms of antibiotic resistance of Clostridioides difficile","volume":"76","author":"Wickramage","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib63","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pro.3819","article-title":"Molecular mechanisms of vancomycin resistance","volume":"29","author":"Stogios","year":"2020","journal-title":"Protein Sci"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib64","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1139\/w2012-002","article-title":"Distribution of the vanG-like gene cluster in Clostridium difficile clinical isolates","volume":"58","author":"Ammam","year":"2012","journal-title":"Can J Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2958.2003.03737.x","article-title":"The vanG glycopeptide resistance operon from Enterococcus faecalis revisited","volume":"50","author":"Depardieu","year":"2003","journal-title":"Mol Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/JB.01980-12","article-title":"Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile","volume":"195","author":"Ethapa","year":"2013","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkx351","article-title":"Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms","volume":"73","author":"Dingsdag","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.07.005_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mib.2022.01.004","article-title":"Mechanisms and impact of antimicrobial resistance in Clostridioides difficile","volume":"66","author":"Dureja","year":"2022","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib69","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41467-020-14382-1","article-title":"Plasmid-mediated metronidazole resistance in Clostridioides difficile","volume":"11","author":"Boekhoud","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0016-5085(03)00902-8","article-title":"Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine","volume":"125","author":"Savidge","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/toxins8050134","article-title":"Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects","volume":"8","author":"Di","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib72","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/iai.47.2.349-352.1985","article-title":"Effects of Clostridium difficile toxins given intragastrically to animals","volume":"47","author":"Lyerly","year":"1985","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/jit426","article-title":"Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain","volume":"209","author":"Kuehne","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib74","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1128\/JCM.38.7.2706-2714.2000","article-title":"Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea","volume":"38","author":"Alfa","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idc.2025.07.005_bib76","first-page":"11","article-title":"Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection","volume":"12","author":"Navalkele","year":"2018","journal-title":"Biologics"},{"issue":"8","key":"10.1016\/j.idc.2025.07.005_bib78","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/648363","article-title":"Clostridium difficile-associated diarrhea and colitis","volume":"16","author":"Gerding","year":"1995","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib79","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.07.005_bib81","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/antibiotics12020224","article-title":"Antibiotic prescribing in outpatient settings: rural patients are more likely to receive fluoroquinolones and longer antibiotic courses","volume":"12","author":"Appaneal","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"10.1016\/j.idc.2025.07.005_bib82","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciy1077","article-title":"What is the role for metronidazole in the treatment of Clostridium difficile infection? Results from a national cohort study of veterans with initial mild disease","volume":"69","author":"Appaneal","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/civ409","article-title":"The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection","volume":"61","author":"Rokas","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib84","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10096-016-2793-7","article-title":"Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country","volume":"36","author":"Lo Vecchio","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz492","article-title":"Oral vancomycin may Be associated with earlier symptom resolution than metronidazole for hospitalized children with nonsevere clostridiodes difficile infections","volume":"6","author":"Yin","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib86","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib87","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkr377","article-title":"A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection","volume":"66","author":"Garey","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib88","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gutjnl-2018-316794","article-title":"Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial","volume":"68","author":"Major","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.idc.2025.07.005_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.anaerobe.2018.10.011","article-title":"A systematic review of the use of rifaximin for Clostridium difficile infections","volume":"55","author":"Ng","year":"2019","journal-title":"Anaerobe"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib90","article-title":"Rifaximin therapy for patients with metronidazole-unresponsive Clostridium difficile infection","volume":"14","author":"Waqas","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib91","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/MIB.0000000000001249","article-title":"Metronidazole or rifaximin for treatment of Clostridium difficile in pediatric patients with inflammatory bowel disease: a randomized clinical trial","volume":"23","author":"Gawronska","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.idc.2025.07.005_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211018654","article-title":"Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review","volume":"14","author":"Gupta","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.idc.2025.07.005_bib93","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jac\/dkaa522","article-title":"Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile","volume":"76","author":"Collins","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.idc.2025.07.005_bib94","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmi.2016.08.017","article-title":"Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study","volume":"22","author":"Gergely Szabo","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00001-22","article-title":"Impact of tigecycline on C. difficile outcomes: case series and propensity-matched retrospective study","volume":"66","author":"Phillips","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib96","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10096-019-03756-z","article-title":"Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence","volume":"39","author":"Kechagias","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.07.005_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw264","article-title":"Does adjunctive tigecycline improve outcomes in severe-complicated, nonoperative Clostridium difficile infection?","volume":"4","author":"LaSalvia","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.07.005_bib98","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jac\/dkv498","article-title":"Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection","volume":"71","author":"Basseres","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib99","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","article-title":"Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study","volume":"17","author":"Vickers","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.07.005_bib100","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/ciad792","article-title":"A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: clinical outcomes with microbiome and metabolome correlates of response","volume":"78","author":"Okhuysen","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.07.005_bib101","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/cid\/ciac096","article-title":"Efficacy, safety, pharmacokinetics, and microbiome changes of ibezapolstat in adults with Clostridioides difficile infection: a phase 2a multicenter clinical trial","volume":"75","author":"Garey","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/1574884714666190328162637","article-title":"Surotomycin (A novel cyclic lipopeptide) vs. Vancomycin for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis","volume":"14","author":"Muhammad","year":"2019","journal-title":"Curr Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.idc.2025.07.005_bib103","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(18)30614-5","article-title":"Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials","volume":"19","author":"Gerding","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T23:13:16Z","timestamp":1761779596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0891552025000686"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.07.005","relation":{},"ISSN":["0891-5520"],"issn-type":[{"type":"print","value":"0891-5520"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Medical Treatment of Clostridioides difficile Infection","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}